Relevance of pro-angiogenic factors secretion in glioblastoma patients
García-Romero Noemí1, IMDEA Nanoscience, Madrid, Spain; Carrión-Navarro Josefa2, Fundación Hospital de Madrid-IMMA, Madrid, Spain; Esteban-Rubio Susana3, Universidad San Pablo CEU, Madrid, Spain; Zafra-Villaverde Antonio4, Universidad San Pablo CEU, Madrid, Spain; Prat-Acín Ricardo, Hospital Universitario la Fe, Valencia, Spain; Fernández-Carballal Carlos, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Belda-Iniesta Cristobal5, Fundación Hospital de Madrid-IMMA, IMDEA Nanoscience, Madrid, Spain; Ayuso-Sacido Angel6, Fundación Hospital de Madrid-IMMA, IMDEA Nanoscience, Universidad San Pablo-CEU, Madrid, Spain.
Glioblastoma multiforme (GBM) is the most prevalent glial tumor, characterized by its heterogeneous population, aggressiveness and poor prognosis. Despite the advances on the surgical approaches in combination with new radio- and/or chemo-therapies the prognosis remains dismal. An important feature of GBM development is the need of new blood vessels that support their maintenance and growth. In this regard, a new generation of small molecules as well as monoclonal antibodies to block angiogenesis have been approved for the treatment of solid tumors. Bevacizumab, a recombinant human monoclonal antibody that neutralizes VEGF-A biological activity, preventing the binding to its receptors in the surface of endothelial cells, and reducing tumor neo-angiogenesis, has proven successful in clinical trials against different tumors like ovarian cancer but the results have been controversial for GBM.
RESULTS AND CONCLUSION
We have evaluated the VEGF-A expression level of three established glioma cell lines, either in vitro or in vivo. Further, we have design cell-specific bevacizumab treatments, for all three cell lines assayed, based on their basal secretion of VEGF-A, in both normoxic and hypoxic conditions. Our data indicate an optimal bevacizumab dose should be established for each patient to improve the treatment outcomes.Format: Poster